Editorial Material
Biochemistry & Molecular Biology
Jeremy Pettus, Schafer C. Boeder, Mark P. Christiansen, Douglas S. Denham, Timothy S. Bailey, Halis K. Akturk, Leslie J. Klaff, Julio Rosenstock, Mickie H. M. Cheng, Bruce W. Bode, Edgar D. Bautista, Ren Xu, Hai Yan, Thai Dung, Satish K. Garg, Samuel Klein
Summary: This study evaluated the safety and efficacy of volagidemab, an antagonistic monoclonal glucagon receptor antibody, as an adjunct to insulin therapy in patients with type 1 diabetes. The results showed that volagidemab reduced daily insulin use and decreased HbA1c levels. However, further research is needed to confirm the long-term efficacy and safety of volagidemab.
Article
Health Care Sciences & Services
Dina H. Griauzde, Grace Ling, Daniel Wray, Melissa DeJonckheere, Kara Mizokami Stout, Laura R. Saslow, Jill Fenske, David Serlin, Spring Stonebraker, Tabassum Nisha, Colton Barry, Rodica Pop-Busui, Ananda Sen, Caroline R. Richardson
Summary: This study compared the changes in HbA1c levels among patients with suboptimally controlled T2DM who were offered intermittently viewed continuous glucose monitor and personalized low-carbohydrate nutrition counseling to those who received usual care. The results showed that the combined approach of continuous glucose monitoring and low-carbohydrate nutrition counseling improved glycemic control in patients with suboptimally controlled T2DM compared to standard care.
JOURNAL OF MEDICAL INTERNET RESEARCH
(2022)
Article
Endocrinology & Metabolism
Sun Joon Moon, Kyung-Soo Kim, Woo Je Lee, Mi Yeon Lee, Robert Vigersky, Cheol-Young Park
Summary: This study evaluated the efficacy of intermittent short-term use of a real-time continuous glucose monitoring (RT-CGM) system in non-insulin-treated patients with uncontrolled type 2 diabetes. The results showed that both treatment groups using the RT-CGM system achieved significant HbA1c reduction at 3 and 6 months, particularly in patients performing self-monitoring of blood glucose (SMBG) frequently.
DIABETES OBESITY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
A. Turquetil, R. Morello, M. Joubert, Y. Le Roux, Y. Reznik
Summary: This study demonstrated that the glycaemic patterns in obese subjects post-bariatric surgery can predict the remission of type 2 diabetes 1 year later. Time spent above range and standard deviation of glucose levels were strong predictors of diabetes remission, with a combination of criteria showing high positive predictive value, sensitivity, and specificity.
DIABETES & METABOLISM
(2021)
Article
Medicine, General & Internal
Lalantha Leelarathna, Mark L. L. Evans, Sankalpa Neupane, Gerry Rayman, Sarah Lumley, Iain Cranston, Parth Narendran, Katharine Barnard-Kelly, Christopher J. J. Sutton, Rachel A. A. Elliott, Vicky P. P. Taxiarchi, Georgios Gkountouras, Matthew Burns, Womba Mubita, Naresh Kanumilli, Maisie Camm, Hood Thabit, Emma G. G. Wilmot
Summary: This study investigated the efficacy of intermittently scanned continuous glucose monitoring in patients with type 1 diabetes. The results showed that compared to traditional fingerstick testing, the use of intermittently scanned continuous glucose monitoring significantly reduced glycated hemoglobin levels and improved blood glucose control.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Endocrinology & Metabolism
I. Dicembrini, C. Cosentino, M. Monami, E. Mannucci, L. Pala
Summary: This study evaluated the impact of CGM and FGM on glycemic control in patients with type 1 diabetes, showing that CGM can reduce HbA1c levels and decrease the risk of severe hypoglycemia.
ACTA DIABETOLOGICA
(2021)
Article
Endocrinology & Metabolism
Jee Hee Yoo, Gyuri Kim, Hyun Jung Lee, Kang Hee Sim, Sang-Man Jin, Jae Hyeon Kim
Summary: This study aimed to evaluate the effectiveness of structured individualized education combined with real-time continuous glucose monitoring (rt-CGM) on glycemic outcomes in adults with type 1 diabetes. The results showed that the education group had better blood glucose control and a reduced high blood glucose index compared to the control group, indicating the positive impact of real-time continuous glucose monitoring combined with individualized education for patients with type 1 diabetes.
DIABETES RESEARCH AND CLINICAL PRACTICE
(2022)
Article
Endocrinology & Metabolism
Ben Broos, Sara Charleer, Nancy Bolsens, Carolien Moyson, Chantal Mathieu, Pieter Gillard, Christophe De Block
Summary: The study found that diabetes knowledge and health literacy impact glycemic control, with higher diabetes knowledge and health literacy scores associated with improved glycemic control.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Cardiac & Cardiovascular Systems
Satomi Wakasugi, Tomoya Mita, Naoto Katakami, Yosuke Okada, Hidenori Yoshii, Takeshi Osonoi, Nobuichi Kuribayashi, Yoshinobu Taneda, Yuichi Kojima, Masahiko Gosho, Iichiro Shimomura, Hirotaka Watada
Summary: This study found that some CGM-derived metrics are significantly associated with arterial stiffness in patients with type 2 diabetes, potentially useful for identifying high-risk patients.
CARDIOVASCULAR DIABETOLOGY
(2021)
Article
Endocrinology & Metabolism
Mengyu Lai, Jianrong Weng, Jiaying Yang, Yujia Gong, Fang Fang, Na Li, Mei Kang, Xianming Xu, Yufan Wang
Summary: This study evaluated the effect of continuous glucose monitoring (CGM) versus self-monitored blood glucose (SMGB) in gestational diabetes mellitus (GDM) with hemoglobin A1c (HbA1c). The results showed that for GDM patients with HbA1c<6%, regular self-monitored blood glucose is a more economical method and can achieve similar glycemic control as CGM, while CGM is beneficial for ideal gestational weight gain (GWG).
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Chemistry, Physical
Jiyong Kim, Salman Khan, Eun Kyu Kim, Hye-Jun Kil, Bo Min Kang, Hyo Geon Lee, Jin-Woo Park, Jun Young Yoon, Woochul Kim
Summary: Continuous monitoring and timely treatment are crucial for wearable and implantable healthcare systems, but they require continuous power supply. We developed a continuous healthcare system for type 1 diabetes by combining a low-energy micropump, self-powered glucose sensor, and body heat conversion to electricity. This system can provide true continuous healthcare for patients.
Article
Endocrinology & Metabolism
Melanie A. Jackson, Andrew Ahmann, Viral N. Shah
Summary: Continuous glucose monitoring plays a crucial role in managing type 1 diabetes, and recent studies suggest its potential benefits in type 2 diabetes as well, improving glycemic control and reducing the risk of hypoglycemia. Further research is needed to explore the utility of CGM in this population.
DIABETES TECHNOLOGY & THERAPEUTICS
(2021)
Review
Endocrinology & Metabolism
Jiaping Lu, Zhen Ying, Ping Wang, Minjie Fu, Chenyu Han, Min Zhang
Summary: This study aimed to assess the efficacy of continuous glucose monitoring (CGM) compared to self-monitoring of blood glucose (SMBG) in maintaining glycemic control among individuals with type 2 diabetes mellitus (T2DM). The results showed that CGM provided greater benefits in glycemic management compared to SMBG, particularly in patients using real-time CGM.
DIABETES OBESITY & METABOLISM
(2023)
Review
Endocrinology & Metabolism
Stacey Uhl, Anuja Choure, Benjamin Rouse, Aggee Loblack, Peter Reaven
Summary: In adults with type 2 diabetes mellitus, the use of continuous glucose monitors (CGMs) led to modest but statistically significant declines in HbA1c levels. The results were consistent for both real-time CGM and flash CGM, with trends favoring real-time CGM for other glucose metrics. However, longer term studies are needed to establish the impact of short-term glucose control improvements on important clinical outcomes.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Review
Endocrinology & Metabolism
Maurizio Gallieni, Cristina De Salvo, Maria Elena Lunati, Antonio Rossi, Francesca D'Addio, Ida Pastore, Gianmarco Sabiu, Roberta Miglio, Gian Vincenzo Zuccotti, Paolo Fiorina
Summary: Diabetic kidney disease is the primary cause of end-stage kidney disease in high-income countries. It is challenging to control glycemic fluctuations in uremic patients, making continuous glucose monitoring an ideal tool for managing diabetes in hemodialysis patients. Studies have shown that continuous glucose monitoring is more accurate and easier to use than glycated hemoglobin testing, especially in patients with type 2 diabetes on hemodialysis.
ACTA DIABETOLOGICA
(2021)
Article
Endocrinology & Metabolism
Georgia Davis, Ryan Bailey, Peter Calhoun, David Price, Roy W. Beck
Summary: The study found that patients with type 2 diabetes using basal insulin without prandial insulin and worse glycemic control at baseline may benefit the most from real-time continuous glucose monitoring (CGM).
DIABETES TECHNOLOGY & THERAPEUTICS
(2022)
Editorial Material
Endocrinology & Metabolism
Roy W. Beck, Richard M. Bergenstal
DIABETES TECHNOLOGY & THERAPEUTICS
(2022)
Article
Endocrinology & Metabolism
Lauren G. Kanapka, John W. Lum, Roy W. Beck
Summary: Insulin pump infusion set failures due to prolonged hyperglycemia occur on average about four times a year, with higher frequency in youth compared to adults. Straight Teflon sets appear to have a higher failure rate than angled Teflon sets and steel sets.
DIABETES TECHNOLOGY & THERAPEUTICS
(2022)
Article
Endocrinology & Metabolism
Shichun Bao, Ryan Bailey, Peter Calhoun, Roy W. Beck
Summary: The study showed that in older adults (65 years and older) with type 2 diabetes using basal insulin without bolus insulin, real-time continuous glucose monitoring (CGM) resulted in a greater increase in time in range (TIR) and reduction in hyperglycemia compared to blood glucose meter (BGM) monitoring.
DIABETES TECHNOLOGY & THERAPEUTICS
(2022)
Article
Endocrinology & Metabolism
Klemen Dovc, Tadej Battelino, Roy W. Beck, Judy Sibayan, Ryan J. Bailey, Peter Calhoun, Christine Turcotte, Stuart Weinzimer, Darja Smigoc Schweiger, Revital Nimri, Richard M. Bergenstal
Summary: This analysis compared the efficacy of the Medtronic advanced hybrid closed-loop (AHCL) system with that of the MiniMed (TM) 670G hybrid closed-loop (HCL) system after the temporary increase of glucose target. The study found that there were similar differences in blood glucose control between the two systems after the use of the temporary target setting and during periods where this setting was not used.
DIABETES TECHNOLOGY & THERAPEUTICS
(2022)
Article
Endocrinology & Metabolism
Jane Lynch, Lauren G. Kanapka, Steven J. Russell, Edward R. Damiano, Firas H. El-Khatib, Katrina J. Ruedy, Courtney Balliro, Peter Calhoun, Roy W. Beck
Summary: This study evaluated the effectiveness of transitioning from standard-of-care management to insulin-only configuration of the iLet bionic pancreas in patients with type 1 diabetes. The results showed that glycemic control improved, with a decrease in HbA1c levels and an increase in time spent within the target range.
DIABETES TECHNOLOGY & THERAPEUTICS
(2022)
Article
Endocrinology & Metabolism
Roy W. Beck, Steven J. Russell, Edward R. Damiano, Firas H. El-Khatib, Katrina J. Ruedy, Courtney Balliro, Zoey Li, Peter Calhoun
Summary: The insulin-only configuration of the iLet((R)) bionic pancreas with fast-acting insulin aspart showed improvement in HbA1c without increasing the risk of hypoglycemia in adults with type 1 diabetes.
DIABETES TECHNOLOGY & THERAPEUTICS
(2022)
Article
Endocrinology & Metabolism
Ryan Bailey, Peter Calhoun, Richard M. Bergenstal, Roy W. Beck
Summary: By comparing the glucose management indicator (GMI) calculated using different durations of data, it was found that there was minimal difference between GMI computed with 7 days and 14 days of data. For most patients, satisfactory estimation of HbA1c can be obtained with 7 days of data.
DIABETES TECHNOLOGY & THERAPEUTICS
(2023)
Article
Endocrinology & Metabolism
Roy W. Beck, Dan Raghinaru, Peter Calhoun, Richard M. Bergenstal
Summary: This study investigated the relationship between the time spent with glucose levels below 70 mg/dL and below 54 mg/dL in patients with diabetes. The results showed that as the time below 70 mg/dL increased, the time below 54 mg/dL also increased. Furthermore, it was found that patients who monitored their glucose levels blindly had more time below 54 mg/dL compared to those who did not, and their data was similar to that of patients using an automated insulin delivery system.
DIABETES TECHNOLOGY & THERAPEUTICS
(2023)
Article
Endocrinology & Metabolism
Maamoun Salam, Ryan Bailey, Peter Calhoun, Janet B. McGill, Richard M. Bergenstal, David Price, Roy W. Beck
Summary: The relationship between mean glucose and HbA1c varies according to race and type of diabetes. Although HbA1c is higher in T2D compared to T1D for the same mean glucose, there is no meaningful difference in the mean glucose-HbA1c relationship between T1D and T2D after accounting for race. The relationship may differ between different racial groups, but seems to be similar between White non-Hispanic and Hispanic individuals. The published glucose management indicator formula appears to be suitable for both T1D and T2D.
DIABETES TECHNOLOGY & THERAPEUTICS
(2023)
Article
Endocrinology & Metabolism
Roy W. Beck, Lauren G. Kanapka, Marc D. Breton, Sue A. Brown, R. Paul Wadwa, Bruce A. Buckingham, Craig Kollman, Boris Kovatchev
Summary: The study evaluated the effect of hybrid-closed loop Control-IQ technology on subgroups based on baseline characteristics in randomized controlled trials. The results showed that Control-IQ had a similar beneficial treatment effect in participants regardless of race/ethnicity, socioeconomic status, prestudy insulin delivery modality, or baseline glycemic control. The greatest improvement was observed in participants with the worst baseline glycemic control.
DIABETES TECHNOLOGY & THERAPEUTICS
(2023)
Editorial Material
Endocrinology & Metabolism
Roy W. Beck
DIABETES TECHNOLOGY & THERAPEUTICS
(2023)
Article
Endocrinology & Metabolism
Nelly R. Mauras, Edward H. Damiano, Firas El-Khatib, Martin Chase Marak, Peter J. Calhoun, Katrina Ruedy, Courtney Balliro, Zoey W. Li, Roy J. Beck, Steven Russell
Summary: This article describes how the bionic pancreas (BP) autonomously doses insulin without carbohydrate counting, using qualitative meal announcements. In case of device malfunction, the BP generates backup insulin doses for injection or pump users, including long-acting insulin dose, a four-period basal insulin profile, short-acting meal doses, and a glucose correction factor. In a 13-week trial, participants using the BP had similar glycemic outcomes compared to those using their prestudy insulin regimen, with both groups having higher mean glucose and lower time-in-range than while using the BP. In conclusion, a backup insulin regimen automatically generated by the BP can be safely implemented if needed.
DIABETES TECHNOLOGY & THERAPEUTICS
(2023)
Article
Endocrinology & Metabolism
Zoey Li, Peter Calhoun, Katrina J. J. Ruedy, Roy W. W. Beck
Summary: The importance of capillary hemoglobin A1c (HbA1c) collection has increased due to its convenience during situations such as the COVID-19 pandemic and virtual visits. This study analyzed 773 paired capillary and venous samples taken from 258 participants and found high congruence between capillary and venous HbA1c values, further confirming the accuracy of capillary measurements as an alternative to venous measurements.
DIABETES TECHNOLOGY & THERAPEUTICS
(2023)